Deciphera Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview

Deciphera Pharmaceuticals

29/04/2024 16:35

* Deciphera Pharmaceuticals Inc  DCPH.OQ   DCPH.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 1 (estimated) for the period ending March 31 2024
    * The Waltham Massachusetts-based  company is expected to
report a
38.5% increase in revenue to $46.307 million from $33.45 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Deciphera
Pharmaceuticals Inc
is for a loss of 55 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Deciphera
Pharmaceuticals Inc is $24.50​, above​ its last closing price
of $14.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.57       -0.58      -0.54     Beat    7
 Jan. 1 2023   -0.60       -0.61      -0.58     Beat    4.7
 Jun. 30 2023  -0.61       -0.62      -0.57     Beat    8.1​
 Mar. 31 2023  -0.58       -0.59      -0.60     Missed  
 ​​Dec.        -0.55       -0.56      -0.60     Missed  -7.6
 31 2022                                                
 Jan. 1 0001               -0.58                        4.6​
 Jun. 30 2022              -0.66                        8.8
 Mar. 31 2022  -0.94       -0.90      -0.80     Beat    11.2
 This summary was machine generated April 29 at 15:35 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)